This coming Thursday, September 24th, I will be participating in the 2nd Annual Livingston Healthcare and Life Science Stakeholders Summit “Capturing Trends and Global Outlook: Advanced and Emerging Technologies.”

The Summit is being held at:

Lighthouse International
111 East 59th Street
New York, NY 10022

Conference Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston Securities, has assembled a dynamic line-up of speakers.

This is a unique and by invitation-only conference (to register, please email Jonathan Mason or call 212-520-8479 ) that brings together key stakeholders from pharmaceutical, capital investment, business strategy and federal science and regulatory segments. This conference will include three topics, which are among the top global issues for investors currently. Attendance in the conference is limited to assure open and interactive dialogue among participants during the sessions and networking breaks. This is intended to collectively identify key trends, as well as mutual opportunities among participants for deal making.

PROGRAM OUTLINE 12:30-5:00pm

INTRODUCTION: Overview and key investment indicators, Mostafa Analoui

SESSION I: Drug Discovery and Development: Early to Mid-Stage Fund Raise and Alliance

– Major Pharma
– Small/Emerging company view

Opening Statements by:

– BJ Bormann, PhD, SVP of Bus Dev & Licensing, Boehringer Ingelheim Pharmaceutical
– Tory Ramaker, Corporate Head of BD, Baxter
– Bill Burkoth, Director of Venture Capital, Pfizer Inc
– Misti Ushio, PhD, VP of Harris & Harris Group
– Eugene Seymour, MD, CEO of Nanoviricides, Inc

SESSION II: Diagnostics: Valuation and Future Directions

– Current Landscape
– Business/technology and finance
– Key future directions

Opening Statements by:

– Mark Dente, MD, VP Healthcare Solution at GE Healthcare
– Gary Fletcher, PhD, Technology R&D, Becton-Dickenson (BD) Diagnostics
– Jonathan White, MD, Head of R&D at Haemonetics
– Douglas Fambrough, MD, Managing Partner, Oxford Bioscience Partners

SESSION III: Global and Emerging Investment Opportunities

– Overview and key players
– SPAC and Healthcare
– Global VCs and PEs

Opening Statements by:

– Michael Nowak, PhD, Yorkville Partners
– Alex Engels, PhD, VP BD Development, Global Medication Delivery, Baxter
– Camilla khevenhueller Borghese, President of ibi, Rome, Italy
– Drs. Shamsi and Parasanna, Acunova Life Sciences, Inc


Invitees include CEOs, CFOs, COOs for a broad range of pharmaceutical, diagnostic, and platform technology companies, a select number of US and International VCs and PEs, along with key policy makers and federal science and regulatory agencies.

I look forward to seeing Scott Livingston, Jonathan Mason, Mostafa Analoui and the participants in NYC on Thursday, September 24th.